linjc16/ctgov huggingface dataset:
Perioperative Pain Management of Pediatric Appendectomy Patients

Study Overview
=================
Brief Summary
-----------------
Acute appendicitis is the most common illness that brings pediatric patients to the hospital for surgical treatment. Abdominal pain is the symptom because of which the patients go to the hospital. Some patients have severe pain and need analgesics before the final diagnosis and before surgery. After surgery most patient experience pain and at least 80 % of the patients need postoperative pain medication. For two decades there has been a clinical guideline for pain management in Kuopio University Hospital (KUH). The investigators aim was to evaluate how well the pain management for pediatric patient works in clinical practice.

Official Title
-----------------
Perioperative Pain Management of Pediatric Appendectomy Patients in Kuopio University Hospital During the Years 2010-2012

Conditions
-----------------
Appendicitis

Intervention / Treatment
-----------------
* Procedure: appendicectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In prospective patients informed consent obtained Appendectomy performed Exclusion Criteria: No informed consent

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| retrospective group<br>Patients whose pain evaluation, analgesics used and details of surgery were collected from patient files | Procedure: appendicectomy<br>* Appendix was removed either laparoscopically or open surgery<br>|
| Prospective group<br>Patients who were interviewed before and after surgery when they were at the hospital | Procedure: appendicectomy<br>* Appendix was removed either laparoscopically or open surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain | pain is asked preoperatively and at the first postoperative day measured with numeral rating scale | from preoperative evaluation until the patient left hospital maximum of 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| amount of opioids used during hospital stay | collected from patient files | from preoperative evaluation until the patient left hospital maximum of 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute appendicitis, pain management, analgesics, pediatric patients, laparoscopy, open surgery
Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients

Study Overview
=================
Brief Summary
-----------------
Superselective IRA infusion of tirofiban may improve myocardial reperfusion and reduce bleeding complications in AMI patients.

Official Title
-----------------
Impacts of Superselective Infarct-related Artery Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in ST Segment Elevation Myocardial Infarction (STEMI) Patients

Conditions
-----------------
Myocardial Infarction

Intervention / Treatment
-----------------
* Procedure: administration of tirofiban by thrombus aspiration catheter in infarct-related artery
* Procedure: administration of tirofiban by guide catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: STEMI patients chest pain for less than 12hr plan to PCI Exclusion Criteria: LM lesion stent thrombosis cardiac shock thrombocytopenia allergy to asprin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: intra-guide-catheter infusion of tirofiban<br> | Procedure: administration of tirofiban by guide catheter<br>* a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI<br>|
| Experimental: intra-thrombus-aspiration-catheter infusion of tirofiban<br> | Procedure: administration of tirofiban by thrombus aspiration catheter in infarct-related artery<br>* a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiovascular events | Infarct size, reinfarction, motality, et.al. | 1 month after PCI | 
| Major adverse cardiovascular events | Infarct size, reinfarction, motality, et.al. | 3 months after PCI | 
| Major Adverse Cardiovascular Events | Infarct size, reinfarction, motality, et.al. | 6 months after PCI | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of participants with bleeding events | bleeding events are assessed by Thrombolysis In Myocardial Infarction(TIMI) criteria | 1 month |
Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children

Study Overview
=================
Brief Summary
-----------------
Severe acute respiratory syndrome (SARS) is a new emerging infectious disease. Its pathogen is a newly discovered coronavirus (SARS-CoV). The clinical course can be classified to 3 stages: viral replication phase, hyperimmune reactive phase, and pulmonary destruction phase. Human monocyte plays a critical role in the initiation of immune response in defending the intracellular pathogens (eg viruses). Monocytes can engulf viruses and present the viral antigens in the major histocompatibility (MHC) molecule to the cell surface to initiate T lymphocyte response. Monocytes also secrete various cytokines to modulate immune response. SARS-CoV is a mutant of animal virus to cause human disease and is able to cause unusual severe respiratory illness. It is suggested the unusual severe disease is due to the intense immune reaction. The investigators will harvest human monocytes from healthy adult and children blood donors. Monocytes would be cultured and infected by SARS-CoV. The change of viral load is monitored after infection. Cytokines secreted by monocytes after infection are also measured. The difference of monocyte cytokine secretion is compared between adults and children. The study is to verify the SARS-CoV infectivity of human monocytes and prove the unusual severity caused by SARS-CoV is related to viral-induced dysregulation of cytokine responses. The results may also clarify why adults tend to have a more severe illness compared with children.

Official Title
-----------------
Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adults aged 20 to 50 years old Healthy children aged 2 to 5 years old

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immunology
Mapping Personality Traits to Genes

Study Overview
=================
Brief Summary
-----------------
Previous research involving families, twins, and adoption all support the idea that there is a substantial heritable aspect to personality. The goal of this research study is to determine how genetics influence heritable personality traits. The work will focus on how genetics affect the chemical messengers which brain cells use to communicate with each other (neurotransmitters). The study involves collecting personality data and DNA samples from related individuals, primarily male siblings and female siblings, but also including parents. Genetic tests performed on these samples will continue to focus on variations in genes, which potentially effect brain neurotransmission. This research has the potential to advance knowledge of genetic influences on human behavior that may be relevant both to normal personality and to psychopathology.

Detailed Description
-----------------
Building on family, twin and adoption studies suggesting that substantial aspects of personality are heritable, research under this protocol explores potential genetic influences on normal personality dimensions. We have previously reported associations between variation in neurotransmitter system genes and variation in personality traits, both across and within families, in a sample of the general population. This study involves collecting personality data and DNA samples from related individuals, primarily male siblings and female siblings, but also including parents. Genetic tests performed on these samples will continue to focus on variations in genes, which potentially affect brain neurotransmission. In some cases, participants are recontacted to specifically investigate whether identified variations in neurotransmitter system genes actually affect neurotransmission. Large population samples are needed in this research, particularly since a new epidemiologically standard population sample will be obtained. This research has the potential to advance knowledge of genetic influences on human behavior that may be relevant both to normal personality and to psychopathology.

Official Title
-----------------
Mapping Personality Traits to Genes

Conditions
-----------------
Mental Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Personality data and DNA samples will be collected from related individuals, primarily pairs of male and pairs of female siblings, but also including parents.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Siblings, Behavior Genetics, Normal Personality, Intelligence, Sixteen Personality Factor Questionnaire, NEO-Personality Inventory (Revised), X-Chromosome
Empyema Treated With tPA & DNAse

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to scientifically evaluate a new substrate for fibrinolysis compared to our standard tPA. The hypothesis, driven by a recent prospective trial, is that tPA may benefit from the addition of DNAse. The primary outcome variable between the two techniques will be length of hospitalization after initiation of treatment.

Official Title
-----------------
Prospective Randomized Trial: Fibrinolysis With tPA (Tissue Plasminogen Activator) Versus tPA and DNAse in Children With Empyema

Conditions
-----------------
Empyema

Intervention / Treatment
-----------------
* Biological: tPA alone
* Biological: tPA plus dornase


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients less than 18 years of age requiring an intervention for empyema by one of the following: Septation or loculation seen on ultrasound or computed tomography or Greater than 10,000 white blood cells identified on pleural tap Exclusion Criteria: Immunodeficiency process Secondary diagnosis or condition that will keep them in the hospital beyond the empyema Existing contraindications to chest tube Documented allergy to one of the study medications

Ages Eligible for Study
-----------------
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: tPA alone<br>tPA alone used to treat empyema | Biological: tPA alone<br> <br> |
| Experimental: tPA plus dornase<br>tPA plus dornase used to treat empyema | Biological: tPA plus dornase<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of stay |  | 3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
empyema, tPA, dornase
Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the treatment effect in patients with upper gastro-intestinal complaints with an elevated risk for NSAID-associated GI-damage to those without an elevated risk for NSAID-associated damage (as determined by the treating physician).

Official Title
-----------------
SYNCHRONISE: Esomeprazole 20 mg Once Daily for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs in Dutch General Practice: The Influence of Risk-Factors for NSAID-Associated GI Damage on Sympton Response

Conditions
-----------------
Heartburn

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with upper gastro-intestinal complaints (defined as heartburn and/or regurgitation and/or nausea and/or bloated feeling)and treatment with esomeprazole 20mg once daily is started because of this (consult 1). Upper gastro-intestinal complaints are thought to be related to NSAID use Patient is using an NSAID** with the following conditions: NSAID use has started at least one week before 1st consultation and is expected to be continued unchanged during the coming period (at least until consult 2) NSAID is taken at least 3 days a week (**)OTC or Prescription NSAID (**)Conventional NSAID or COX-2 selective NSAID Exclusion Criteria: Use of a PPI and/or H2RA in the month preceding the study A history of reflux disease, not related to NSAID use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PPI, upper GI-symptoms, heartburn, NSAID, risk, Bloating, Regurgitation
Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery

Study Overview
=================
Brief Summary
-----------------
In this study we wanted to determine if perioperative administration of olanzapine prior to knee or hip replacement surgery in high risk patients would prevent the onset of postoperative delirium.

Detailed Description
-----------------
Postoperative delirium is a serious and common (20% to 60%) complication in orthopedic surgery patients. In this study we investigate whether prophylactic administration of olanzapine can prevent delirium from occurring after knee or hip replacement in high-risk patients > 65 years of age. This is a randomized, double-blind, single center, placebo-controlled study.

Official Title
-----------------
A Double-Blind, Randomized, Placebo-Controlled Study of Perioperative Administration of Olanzapine to Prevent Postoperative Delirium in Joint Replacement Patients

Conditions
-----------------
Delirium

Intervention / Treatment
-----------------
* Drug: olanzapine
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: High risk for delirium age > 65 history of delirium medical comorbidities ability to give informed consent Exclusion Criteria: Dementia Alcohol abuse Current use of an antipsychotic Allergy to olanzapine

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Drug: olanzapine<br>* 5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor<br>* Other names: Zyprexa;|
| Placebo Comparator: 2<br> | Drug: placebo<br>* placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of delirium |  | days in hospital | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications, length of stay, hospital costs |  | days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
delirium, atypical antipsychotics, olanzapine, orthopedic
Severe Pregnancy Complications Are Associated With Elevated Factor VIII Plasma Activity

Study Overview
=================
Brief Summary
-----------------
Congenital and acquired thrombophilia were identified as risk factors for thrombosis in systemic vessels.Thrombophilias have also been recently found to be associated with preeclampsia, intrauterine fetal growth restriction (IUGR), placental abruption, intrauterine fetal death (IUFD) and repeated pregnancy loss.These severe pregnancy complications are thought to result from thrombotic events occurring in the uteroplacental circulation. Accumulating data have established an association between elevated plasma activity of factor VIII and thrombosis although the mechanism is still not defined and elevated factor VIII activity is now regarded as being equivalent to thrombophilia. We intend to investigatthe association between factor VIII levels and severe pregnancy complications which are considered to result from placental vascular pathology, i.e., preeclampsia, IUGR, placental abruption and IUFD. We hypothezise that the prevalence of elevated factor 8 will be higher among women with pregnancy complications compared to controls.

Official Title
-----------------
A Retrospective Analysis of Possible Association Between Severe Pregnancy Complications and Elevated Factor VIII Plasma Activity.

Conditions
-----------------
Preeclampsia, Pregnancy Complications, Placental Abruption, Intrauterine Fetal Growth Restriction, Intrauterine Fetal Death

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who had either normal pregnancy or complicated pregnancy. Exclusion Criteria: Other causes of pregnancy complication such as infections, anomalies and fetal malformations

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>The study group included 49 patients with a previous history of one or more of the following pregnancy complications: preeclampsia (n = 17), severe IUGR (n = 13), IUFD (n = 14) or placental abruption (n = 5). | |
| 2<br>The control group included 49 healthy women who delivered during the study period, who did not smoke during pregnancy and in whom pregnancy and delivery were uneventful | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalenc of elevated factor VIII |  | RETROSPECTIVE | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pregnancy complications: preeclampsia , severe IUGR , IUFD or placental abruption (n = 5).
An Observational Pilot Study to Characterize Relationships Between Self-reported Information, Game Performance, and Passive Physiology Measures Throughout a Daily Cycle

Study Overview
=================
Brief Summary
-----------------
This study intends to collect self-reported information with multiple surveys about lifestyle habits, food and drink, state of mind (happy, sad, etc.) and traits (decision making, general personality, etc.) The purpose of this study is to understand relationships between self-reported information, game performance, and passive physiology measures throughout a daily cycle.

Official Title
-----------------
An Observational Pilot Study to Characterize Relationships Between Self-reported Information, Game Performance, and Passive Physiology Measures Throughout a Daily Cycle

Conditions
-----------------
Energy and Cognition

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be >=18 years old Must agree to participate via electronic consent Must agree to share e-mail and physical address (final dataset de-identified) Must own a computer and/or smartphone Must be a member of the survey panel and agree to take multiple surveys over 4-6 weeks Must complete the full surveys and not fail attention filters Must be able to access cognition games website and play the games Must be willing to wear a lifestyle assessment sensing device for 1 week Exclusion Criteria: Known skin reaction or allergy to metal Known skin reaction or allergy to medical adhesive Participation in another research study, behavior or new drug testing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To test the hypothesis that there are relationships between self-reported information, game performance, and passive physiology measures throughout a daily cycle. |  | 4-6 weeks |